Ferroptosis Activators
| Cat. No. | Product Name / Activity |
|---|---|
| 5449 | Erastin |
| Ferroptosis activator; also mitochondrial VDAC modulator | |
| 6280 | FIN 56 |
| Ferroptosis activator | |
| 0218 | L-Glutamic acid |
| Induces ferroptosis; endogenous, non-selective agonist | |
| 6954 | L-Buthionine sulfoximine |
| Induces ferroptosis by inhibiting glutathione synthesis | |
| 6429 | ML 210 |
| Induces ferroptosis in tumor initiation cells; glutathione peroxidase inhibitor | |
| 6118 | 1S,3R-RSL3 |
| Induces ferroptosis; inhibits glutathione peroxidase 4 (GPX4) | |
| 1965 | Simvastatin |
| Induces ferroptosis; also HMG-CoA reductase inhibitor | |
| 6814 | Sorafenib |
| Induces ferroptosis; also Raf-1, VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and cKIT inhibitor | |
| 4935 | Sulfasalazine |
| Ferroptosis inducer; cystine-glutamate antiporter inhibitor and inhibitor of NF-κB activation |
Cancer Research Product Guide
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyRequest PDFMAPK Signaling Review
Our MAPK signaling review gives an overview of the MAPK signaling cascade and summarizes small molecule inhibitors of the pathway.
Request copyRequest PDFAlzheimer's Life Science Poster
Written by Alan Palmer
Our Alzheimer's disease poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDFParkinson's Life Science Poster
Written by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF